An interventional study of Supplementation of Moringa oleifera leaf powder in Type 2 Diabetes, sponsored by University of Milan. Completed at 1 site in Algeria. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-24.
Sponsored by University of Milan · Not applicable, Interventional, and Treatment
The objective of this clinical trial was to understand whether supplementation of Moringa oleifera leaf powder improved glycemic management in Sahrawi women with type 2 diabetes living in refugee camps. The main question sought to be answered was:
Researchers compared Moringa supplementation with no Moringa consumption to see if Moringa oleifera worked to improve glycemic control.
Participants had to:
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
This study's enrollment of 52 is below the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →University of Milan is the lead sponsor of 183 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The experimental group received for 3 months a daily supplementation of 10g of Moringa oleifera leaf powder to consume within the two main meals.
Dietary Supplement: Supplementation of Moringa oleifera leaf powder
The control group were asked to refrain from consuming Moringa oleifera leaves throughout the study period (3 months).
Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
Glycosylated hemoglobin (HbA1c)
Time frame: Glycosylated hemoglobin was measured at recruitment and at the end of the study (three months)
Fasting glucose
Time frame: Fasting glucose was measured at recruitment and at the end of the study (three months)
BMI
Time frame: BMI were measured at recruitment and at the end of the study (3 months)
Waist circumference
Time frame: Waist circumference were measured at recruitment and at the end of the study (3 months)
Hip circumference
Time frame: Hip circumference were measured at recruitment and at the end of the study (3 months)
% body fat
Time frame: % of body fat were measured at recruitment and at the end of the study (3 months)
Blood pressure
Systolic and diastolic blood pressure
Time frame: Systolic and diastolic blood pressure were measured at recruitment and at the end of the study (3 months)
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.